NFKB1 and COVID-19: As such, the inhibition of NF-κB would allow the targeting of multiple cytokines/chemokines which are expected to have much higher therapeutic potential than a single cytokine target to prevent the further cascade, especially for the critical stage COVID-19 patients, without the inhibition of antiviral cytokines such as IFN-γ [61].